Yet, advances in precision drugging of the BRAF p.V600E mutation alone with BRAF inhibitors have now extended the survival of numerous melanoma, thyroid, and non-small cell lung cancer (NSCLC) patients worldwide13. This evidence concerns the gene BRAF and non-small cell lung carcinoma.